Constantine Mitsiades, ASH 2018 – Latest Developments in the Treatment of Multiple Myeloma
In this interview, filmed at ASH 2018, Dr Constantine Mitsiades talks to touchONCOLOGY about the current and future treatment landscape of multiple myeloma. One of the most significant recent developments in the treatment of multiple myeloma, has been monoclonal antibodies (mAbs), particularly daratumumab. This anti-CD31 mAb has been approved, alone and in combination with other agents, by the US Food and Drug Administration and there are ongoing studies into other combinations. Dr Mitsiades discusses the issues around treating patients who become refractory to daratumumab and how there is still much to learn regarding optimal drug combinations and delivery methods. Looking to the future, Dr Mitsiades describes CRISPR-based functional genomic technologies and how they can be used to learn more about the genes involved in multiple myeloma. He is also interested in how next generation sequencing can be used to derive important information from the non-malignant cells of the tumour micro-environment.
1. What have been the most significant recent developments in the treatment of multiple myeloma? (0:10)
2. What are the current unmet needs and the challenges you face when treating patients? (2:16)
3. What developments are you most excited about in your area over the next few years? (4:07)
4. Which presentations/data have interested you the most at ASH 2018? (5:45)
Speaker disclosures: Constantine Mitsiades has nothing to disclose in relation to this interview.
Filmed at the 60th American Society of Hematology (ASH) 2018 Annual Meeting, San Diego, CA, US, 1–4 December 2018.
Share this Video
Related Videos In Multiple Myeloma
Shaji Kumar, ASH 2022: Promising new agents enhancing the treatment of multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses some promising new agents for the treatment of multiple myeloma, including immunotherapies like CAR-T cell therapies, as well as data from novel bispecific antibodies in the context of relapsed or refractory multiple myeloma. Abstract 158: Elranatamab, a BCMA Targeted T-Cell Engaging Bispecific Antibody, Induces Durable Clinical and Molecular […]
Shaji Kumar, ASH 2022: Highlights in older, frail transplant ineligible patients with multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the results of some key clinical trials presented at ASH 2022 in the field of older, frail transplant ineligible patients with multiple myeloma. Abstract 4553: Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis (00:25-00:57) Abstract 569: A Dexamethasone Sparing-Regimen […]
Shaji Kumar, ASH 2022: Updated efficacy analysis from the phase III MAIA study in newly-diagnosed multiple myeloma
Dr Shaji Kumar (Mayo Clinic, MN, USA) discusses the updated efficacy analysis from the phase III MAIA study presented at the recent ASH 2022 congress. There were also some additional post-hoc efficacy analyses on key subgroups (Abstracts 4553 and 3245). Abstract 3245: Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!